

R1 R2 R3 PG0 PG1 Estagiário Tecnólogo
PIBIC Last Name - Tamaki First Name - Celina Middle -

Service (sector) Low Vision N° CEP

VALIDATION OF THE MNREAD PORTUGUESE CONTINUOUS-TEXT READING-ACUITY CHART

Tamaki,C.; Kallie, C.; Salomão, S.R.

Purpose: The MNREAD Acuity Charts are continuous-text reading-acuity charts that were developed at the Minnesota Laboratory for Low-Vision Research at the University of Minnesota. These charts are the most suitable for measuring the reading acuity and reading speed of normal and low-vision patients. The purpose of this study was to validate the recently developed MNREAD-Portuguese: a tool for measuring reading performance as a function of text size. Methods: Twenty subjects with normal vision (20/20 or better, with best refractive correction) were tested on the MNREAD-Portuguese. The same subjects previously read a passage of text, representing normal, day-to-day reading. Reading speeds in words per minute (wpm) were recorded for both the MNREAD and the text passage. Testing procedure for MNREAD and 92-word text passage: Testing was taken at 40 cm. The subjects were instructed to read the test sentences aloud, as quickly and accurately as possible. A blank piece of card was used to cover the sentences below the one that was read (to prevent previewing the subsequent sentences). A stopwatch was used to record the time taken to read each sentence. Times and errors, including missed or incorrectly read words, were noted on the score sheet. Results: Sentences in the MNREAD-Portuguese chart are sufficiently consistent to provide reliable measures of reading abilities. Reading speeds for the passage (log Mar = 0.6) were $N(175.7,24.8)$. Reading speeds for the MNREAD-Portuguese at log MAR = 0.6 were $N(186.5,23.0)$. The correlation between the two measures was $r = 0.891$. Conclusion: The MNREAD-Portuguese test is reliable and consistent in calculating measures of reading as a function of text size in normally sighted individuals. This validation procedure provides evidence that artifacts of the testing device will not confound future data collected from low-vision patients.